Blockchain Registration Transaction Record

VERAXA Biotech Unveils BiTAC-ADC Platform Data, Targets Solid Tumors

VERAXA Biotech releases new in vitro data for its BiTAC-ADC platform, showing tumor-specific killing of breast cancer cells with reduced toxicity. The company seeks partnerships at BIO 2026.

VERAXA Biotech Unveils BiTAC-ADC Platform Data, Targets Solid Tumors

This news matters because VERAXA's BiTAC-ADC platform could revolutionize cancer treatment by precisely targeting tumors while sparing healthy cells, reducing debilitating side effects. For patients with solid tumors like breast cancer, this technology offers hope for more effective and safer therapies. The company's pursuit of partnerships at BIO 2026 signals potential accelerated development and broader access to these innovative treatments.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x47eeeac44e7cbd1d36b73ac415ba10daf01b5965f52c1846596f8552c3687645
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintplumyZur-b8a10e3841c426cf3fb61ebd057c67d8